Global Information
회사소개 | 문의

비소세포 폐암(NSCLC) : 파이프라인 리뷰

Non-Small Cell Lung Cancer - Pipeline Review, H1 2018

리서치사 Global Markets Direct
발행일 2018년 06월 상품 코드 232838
페이지 정보 영문 3034 Pages
가격
US $ 2,500 ₩ 2,852,200 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,704,500 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,556,700 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


비소세포 폐암(NSCLC) : 파이프라인 리뷰 Non-Small Cell Lung Cancer - Pipeline Review, H1 2018
발행일: 2018년 06월 페이지 정보 : 영문 3034 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

비소세포 폐암(NSCLC)은 가장 많이 볼 수 있는 폐암의 일종으로 폐 조직이나 기도 세포로부터 발생하는 암(악성 종양)입니다. 흡연은 폐암의 가장 큰 원인이며, 폐암 증상은 일반적으로 후기에 나타납니다. 징조와 증상에는 지속성 기침, 호흡 곤란, 숨참, 항상적인 흉통과 불쾌감, 혈담, 피로, 허약, 의도하지 않은 체중 감소 등을 들 수 있습니다. 치료에는 투약, 화학요법, 생활 방식 변경 등이 포함됩니다.

비소세포 폐암(Non-Small Cell Lung Cancer) 치료제 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

서론

비소세포 폐암 개요

치료제 개발

비소세포 폐암 : 기업에서 개발중인 치료제

비소세포 폐암 : 대학/기관에서 연구중인 치료제

비소세포 폐암 : 파이프라인 제품 개요

비소세포 폐암 : 기업에서 개발중인 제품

비소세포 폐암 : 대학/기관에서 연구중인 제품

비소세포 폐암 치료제 개발에 참여하고 있는 기업

비소세포 폐암 : 치료제 평가

약제 개요

비소세포 폐암 : 휴지중인 프로젝트

비소세포 폐암 : 개발이 중지된 제품

비소세포 폐암 : 제품 개발 마일스톤

부록

KSM 16.08.03

영문목차

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H1 2018, provides an overview of the Non-Small Cell Lung Cancer (Oncology) pipeline landscape.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in later stages of the disease. The signs and symptoms include persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness and unintentional weight loss. The disease might be controlled with the help of medications, chemotherapy and modifications in lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Small Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 9, 1, 49, 238, 205, 16, 175, 30 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 13, 14, 46 and 5 molecules, respectively.

Non-Small Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Non-Small Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Non-Small Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Non-Small Cell Lung Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • Introduction 14
  • Non-Small Cell Lung Cancer - Overview 15
  • Non-Small Cell Lung Cancer - Therapeutics Development 16
  • Non-Small Cell Lung Cancer - Therapeutics Assessment 95
  • Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development 131
  • Non-Small Cell Lung Cancer - Drug Profiles 283
  • Non-Small Cell Lung Cancer - Dormant Projects 2900
  • Non-Small Cell Lung Cancer - Discontinued Products 2927
  • Non-Small Cell Lung Cancer - Product Development Milestones 2937
  • Appendix 2956

List of Tables

  • Number of Products under Development for Non-Small Cell Lung Cancer, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by 3-V Biosciences Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by 3SBio Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by 4D Pharma PLC, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by 4SC AG, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Ability Pharmaceuticals SL, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Abpro, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by ACEA Biosciences Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Adamed Sp z oo, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Aduro BioTech Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Advantagene Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Advaxis Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories LLC, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Agenus Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by AlfaSigma SpA, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Altimmune Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Altor BioScience Corp, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Amgen Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by AndroScience Corp, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Apexigen Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Aptose Biosciences Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Arcus Biosciences Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Ariad Pharmaceuticals Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by ARMO Biosciences Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by ArQule Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Array BioPharma Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Asana BioSciences LLC, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Astellas Pharma Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Asterias Biotherapeutics Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by AstraZeneca Plc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Atreca Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Aurobindo Pharma Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Basilea Pharmaceutica Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Batu Biologics Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Bavarian Nordic A/S, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Bayer AG, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by BeiGene Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by BerGenBio ASA, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Beta Pharma Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Bicycle Therapeutics Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Bio-Cancer Treatment International Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by BioAtla LLC, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Biocad, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by BioCancell Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Biocon Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by BioLineRx Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Biothera Pharmaceutical Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Blueprint Medicines Corp, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Boston Biomedical Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by BriaCell Therapeutics Corp, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by BrightPath Biotherapeutics Co Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Co, H1 2018

List of Figures

  • Number of Products under Development for Non-Small Cell Lung Cancer, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Top 10 Routes of Administration, H1 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
La Merie Publishing
BCC Research